A Phase I Study of CDK4/6 Inhibitor LEE011 Combined With Gemcitabine in Patients With Advanced Solid Tumors or Lymphoma
Phase of Trial: Phase I
Latest Information Update: 22 Sep 2016
At a glance
- Drugs Ribociclib (Primary) ; Gemcitabine
- Indications Lymphoma; Solid tumours
- Focus Adverse reactions
- 09 Sep 2016 Status changed from active, no longer recruiting to discontinued as PI left institute.
- 14 Mar 2016 Status changed from recruiting to active, no longer recruiting, according to ClinicalTrials.gov record.
- 06 Aug 2015 Patient inclusion and exclusion criteria been amended.